ArrowMark Colorado Holdings LLC Sells 9,397 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

ArrowMark Colorado Holdings LLC reduced its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 1.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 521,889 shares of the company's stock after selling 9,397 shares during the quarter. ArrowMark Colorado Holdings LLC owned 0.72% of Kiniksa Pharmaceuticals worth $10,323,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. KLP Kapitalforvaltning AS acquired a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $158,000. Tower Research Capital LLC TRC increased its position in Kiniksa Pharmaceuticals by 117.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock worth $168,000 after buying an additional 4,575 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of Kiniksa Pharmaceuticals by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock valued at $174,000 after purchasing an additional 1,004 shares during the period. Teacher Retirement System of Texas lifted its holdings in shares of Kiniksa Pharmaceuticals by 7.1% in the 4th quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock valued at $215,000 after buying an additional 719 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Kiniksa Pharmaceuticals during the 4th quarter valued at approximately $258,000. Institutional investors own 53.95% of the company's stock.

Insider Activity at Kiniksa Pharmaceuticals

In related news, CAO Michael R. Megna sold 9,051 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.45, for a total value of $203,194.95. Following the completion of the transaction, the chief accounting officer now owns 26,528 shares in the company, valued at $595,553.60. This trade represents a 25.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ross Moat sold 6,272 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $28.00, for a total value of $175,616.00. Following the completion of the transaction, the insider now directly owns 9,415 shares in the company, valued at approximately $263,620. This represents a 39.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 224,820 shares of company stock valued at $5,386,361 over the last three months. 54.57% of the stock is owned by insiders.

Kiniksa Pharmaceuticals Trading Down 0.6 %

Shares of KNSA stock traded down $0.17 during trading hours on Wednesday, hitting $26.77. 441,892 shares of the company were exchanged, compared to its average volume of 480,532. The company has a market capitalization of $1.94 billion, a PE ratio of -191.20 and a beta of 0.07. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $17.38 and a 52 week high of $28.56. The business has a 50 day moving average of $22.20 and a two-hundred day moving average of $21.37.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.09. The business had revenue of $137.79 million during the quarter, compared to the consensus estimate of $128.35 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals's revenue was up 72.5% on a year-over-year basis. During the same period last year, the business posted ($0.25) EPS. On average, research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Jefferies Financial Group increased their target price on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Citigroup started coverage on Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a "buy" rating and a $40.00 price target for the company. Finally, Wedbush reissued an "outperform" rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $38.80.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.